Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial

BACKGROUND: The failure rate after neoadjuvant chemoradiotherapy followed by surgery is approximately 34.6%–48% for resectable esophageal carcinoma. Pathologic complete response after neoadjuvant chemoradiotherapy is an important factor in predicting lower recurrence and better survival. Whether the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jinsong, Huang, Ai, Yang, Kunyu, Jiang, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015937/
https://www.ncbi.nlm.nih.gov/pubmed/36922805
http://dx.doi.org/10.1186/s12885-023-10687-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015937/
https://www.ncbi.nlm.nih.gov/pubmed/36922805
http://dx.doi.org/10.1186/s12885-023-10687-8

Ejemplares similares